Rifamycin Sodium

Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization The recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H. pylori infection. Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologists Additionally, new data describing the foundations for Talicia's recent FDA-approved label change to a more convenient three-times daily (TID) "breakfast, lunch, and dinner" dosing routine, supporting patient adherence, has been published in the Journal of Clinical Pharmacology The published data describe the use of physiologically-based pharmacokinetic (PBPK) modeling and simulation to demonstrate pharmacokinetic equivalence of the TID regimen to the previous every 8-hour (Q8H) dosing regimen H. pylori infection affects approximately 35% of the U.S. adult population and is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease RALEIGH, N.C. and TEL-AVIV, Israel, Jan. 21, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the coverage of Talicia by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without the requirement for prior therapeutic steps or authorizations, for both treatment-naïve and treatment-experienced patients, effective as of January 1, 2025. "There is broad recognition of the clinical efficacy of Talicia and the recently updated American College of Gastroenterology (ACG) Clinical Guideline, listing Talicia as a first-line treatment option. Talicia is the only FDA-approved low-dose rifabutin-based therapy for the eradication of H. pylori, and continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologists1," said Rick D. Scruggs, President and Chief Commercial Officer of RedHill Biopharma, Inc. "We are pleased that coverage in the Medicare arena is growing as the Part D payers recognize the importance of treating H. pylori with the right therapy the first time and look forward to expanding coverage in Medicare." The Company also announced the publication of new data in The Journal of Clinical Pharmacology2. The published data describe the foundations for Talicia's recently FDA-approved label change to a more convenient three-times daily (TID) with food (at least 4 hours apart, e.g., breakfast, lunch, and dinner) dosing routine, further simplifying the patient experience and supporting increased patient adherence. The result of a successful collaboration with Certara, the published study utilized Certara's Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling and simulation to demonstrate pharmacokinetic equivalence in plasma and within the stomach for all three of Talicia's components, regardless of dosing TID or Q8H. These data support the provision of a more patient-friendly Talicia regimen and further demonstrate RedHill's ongoing commitment to enhanced patient experience and outcomes. "Treating H. pylori infection is challenging and often requires patients to take multiple different pills multiple times a day. Simplified dosing regimens improve patient adherence. In the treatment of H. pylori infection, adherence to dosing is critical for optimizing patient outcomes, while also mitigating against the development of bacterial resistance. Therefore, it is important to use an effective therapy that is most likely to eradicate H. pylori infection at the first attempt," said Colin W. Howden, MD, Professor Emeritus, University of Tennessee College of Medicine, and co-author of the paper. "These important data, and the retention of Talicia's pharmacokinetic profile across dosing regimens, support the change to a more simplified TID dosing schedule. Talicia's efficacy, tolerability, and resistance profile, along with its convenient all-in-one formulation and TID dosing, further support its inclusion as an empirically prescribed first-line option in the 2024 ACG Clinical Guideline on the treatment of H. pylori infection3." About H. pylori H. pylori is a bacterial infection that affects approximately 35%4 of the U.S. population, with an estimated two million patients treated annually3. Worldwide, around 66% of the population has H. pylori infection5, which is classified by the World Health Organization (WHO) as a Group 1 carcinogen. It remains the strongest known risk factor for gastric cancer6 and a major risk factor for peptic ulcer disease7 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma8. More than 27,000 Americans are diagnosed with gastric cancer annually9. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics – especially clarithromycin – which is still commonly used in standard combination therapies10. About Talicia® Talicia is the only low-dose rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria seen with other antibiotics. More specifically, the high rates of H. pylori resistance to clarithromycin have led to significant increases in treatment failures with clarithromycin-based therapies and are a strong public health concern, as highlighted by the ACG, FDA and the WHO in recent years. Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults. In the pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). Minimal to zero resistance to rifabutin, a key component of Talicia, was detected in RedHill's pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent11 to their therapy had response rates of 90.3% in the Talicia arm vs. 64.7% in the active comparator arm12. Talicia is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide. Patients should check coverage details with their health plan. TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial­­, indicated for the treatment of Helicobacter pylori infection in adults. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. IMPORTANT SAFETY INFORMATION Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin. Talicia is contraindicated in patients receiving rilpivirine-containing products. Talicia is contraindicated in patients receiving delavirdine or voriconazole. Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin. Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia. Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin. Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins. Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis. Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia. Talicia should not be used in patients with hepatic impairment or severe renal impairment. Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease. The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis. To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or . Full prescribing information for Talicia is available at . About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S commercialization and development of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults13. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. government and academic collaborations for development for radiation and chemical exposure indications such as Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 ( upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease. More information about the Company is available at / X.com/RedHillBio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential effects of Talicia® in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, and that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. All information contained herein is the sole responsibility of RedHill Biopharma Ltd. Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma +972-54-6543-112 [email protected] Category: Commercial 1 IQVIA XPO Data on file 2 Vakil N, Howden CW, Shah SC, Chen KF, Offman E, Almenoff JS, Sheldon KL. Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication. J Clin Pharmacol. 2025 Jan 2. doi: 10.1002/jcph.6178. Epub ahead of print. PMID: 39745109. 3 Chey, William D. MD, FACG1; Howden, Colin W. MD, FACG2; Moss, Steven F. MD, FACG3; Morgan, Douglas R. MD, MPH, FACG4; Greer, Katarina B. MD, MSEpi5; Grover, Shilpa MD, MPH6; Shah, Shailja C. MD, MPH7. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology 119(9):p 1730-1753, September 2024. | DOI: 10.14309/ajg.0000000000002968 4 Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429. 5 6 Lamb A et al. Role of the Helicobacter pylori–Induced inflammatory response in the development of gastric cancer. J Cell Biochem 2013;114.3:491-497. 7 NIH – Helicobacter pylori and Cancer, September 2013. 8 Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomarker research 2016;4.1:15. 9 National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). 10 Malfertheiner P. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664; O'Connor A. et al. Treatment of Helicobacter pylori Infection 2015, Helicobacter 20 (S1) 54-61; Venerito M. et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88(1):33-45. 11 Defined as the PK population which included those subjects in the ITT population who had demonstrated presence of any component of investigational drug at visit 3 (approx. day 13) or had undetected levels drawn >250 hours after the last dose. 12 The pivotal Phase 3 study with Talicia® demonstrated 84% eradication of H. pylori infection with Talicia® vs. 58% in the active comparator arm (ITT analysis, p<0.0001). 13 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo - SOURCE RedHill Biopharma Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

统计每周仿制药一致性评价申报、上市申请（12.23-12.29）  1、仿制药上市申请获批药品名称企业名称类型受理号阿奇霉素干混悬剂海南斯达制药有限公司;海南赛立克药业有限公司4CYHS2301549艾曲泊帕乙醇胺干混悬剂山东则正医药技术有限公司;湖南九典制药股份有限公司3CYHS2303319贝前列素钠片江苏和晨药业有限公司4CYHS2302529玻璃酸钠滴眼液广东汉丰百盛医药有限公司;珠海亿胜生物制药有限公司4CYHS2302162布美他尼注射液新乡市常乐制药有限责任公司3CYHS2302028碘美普尔注射液成都倍特药业股份有限公司4CYHS2300806碘美普尔注射液重庆圣华曦药业股份有限公司4CYHS2300398二甲双胍恩格列净片(Ⅴ)浙江诺得药业有限公司4CYHS2302084二甲双胍恩格列净片(Ⅵ)浙江诺得药业有限公司4CYHS2301714二甲双胍恩格列净片(Ⅵ)杭州朱养心药业有限公司4CYHS2301799枸橼酸西地那非口崩片金鸿药业股份有限公司4CYHS2300933聚乙二醇钠钾散山东新华鲁抗医药有限公司;山东鲁抗医药集团赛特有限责任公司4CYHS2201777利丙双卡因乳膏海南海灵化学制药有限公司4CYHS2300688硫酸镁钠钾口服用浓溶液南京海鲸药业股份有限公司4CYHS2301975硫酸镁钠钾口服用浓溶液维生原（厦门）生物科技有限公司;江苏万高药业股份有限公司4CYHS2301214罗沙司他胶囊湖南明瑞制药股份有限公司4CYHS2301616罗沙司他胶囊江西山香药业有限公司4CYHS2301375罗沙司他胶囊江西山香药业有限公司4CYHS2301376罗沙司他胶囊南京正大天晴制药有限公司4CYHS2301366罗沙司他胶囊南京正大天晴制药有限公司4CYHS2301367乳果糖口服溶液青岛黄海制药有限责任公司4CYHS2302134乳果糖口服溶液青岛黄海制药有限责任公司4CYHS2302135乳果糖口服溶液保定爱晖药业有限公司4CYHS2301666他达拉非片湖南威特制药股份有限公司4CYHS2302456他达拉非片广东九明制药有限公司4CYHS2302381吸入用复方异丙托溴铵溶液南京力成药业有限公司4CYHS2302748西甲硅油乳剂维生原（厦门）生物科技有限公司;江苏万高药业股份有限公司4CYHS2302283盐酸奥洛他定滴眼液石家庄格瑞药业有限公司4CYHS2302351盐酸奥洛他定滴眼液石家庄格瑞药业有限公司4CYHS2302350盐酸布比卡因注射液江西和盈药业有限公司;江西银涛药业股份有限公司3CYHS2301026盐酸利多卡因局部溶液浙江赛默制药有限公司3CYHS2400324盐酸普萘洛尔片合肥国药诺和药业有限公司;华益药业科技(安徽)有限公司3CYHS2400861依托咪酯中/长链脂肪乳注射液燃点（南京）生物医药科技有限公司;江苏康禾生物制药有限公司4CYHS2302459依折麦布片山东新时代药业有限公司4CYHS2300782注射用甲磺酸齐拉西酮南京正大天晴制药有限公司4CYHS2302315注射用磷酸特地唑胺四川美大康佳乐药业有限公司;峨眉山通惠制药有限公司4CYHS2302155左氧氟沙星滴眼液湖北远大天天明制药有限公司4CYHS2301688 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号阿莫西林胶囊国药集团汕头金石制药有限公司CYHB2450017阿莫西林克拉维酸钾干混悬剂国药集团威奇达药业有限公司CYHB2350931醋酸泼尼松片浙江仙琚制药股份有限公司CYHB2150103对乙酰氨基酚片石家庄四药有限公司CYHB2450177对乙酰氨基酚片石家庄四药有限公司CYHB2450176法莫替丁注射液华润双鹤利民药业（济南）有限公司CYHB2350536呋塞米注射液石家庄四药有限公司CYHB2450147复方电解质注射液成都国为生物医药有限公司;四川科伦药业股份有限公司CYHB2350782复方氯化钠注射液广东科伦药业有限公司CYHB1950827甘露醇注射液河南科伦药业有限公司CYHB2050048格列美脲片悦康药业集团股份有限公司CYHB2450084格列齐特缓释片山东司邦得制药有限公司CYHB2450198喷他佐辛注射液华润双鹤药业股份有限公司CYHB2350459碳酸氢钠注射液辽宁民康制药有限公司;湖南科伦制药有限公司CYHB2350797维生素B6注射液湖北科伦药业有限公司CYHB2350932盐酸氨基葡萄糖胶囊北京康必得药业有限公司CYHB1950937盐酸氨溴索片黑龙江澳利达奈德制药有限公司CYHB2350642盐酸苯海拉明片安徽博诺美科生物医药有限公司;上海华源安徽锦辉制药有限公司CYHB2450078盐酸纳美芬注射液辽宁海思科制药有限公司CYHB2450045注射用厄他培南钠石药集团欧意药业有限公司CYHB2450089注射用磷霉素钠厦门宝瑞药业有限公司;国药集团国瑞药业有限公司CYHB2350981注射用磷霉素钠厦门宝瑞药业有限公司;国药集团国瑞药业有限公司CYHB2350982注射用磷霉素钠厦门宝瑞药业有限公司;国药集团国瑞药业有限公司CYHB2350983注射用头孢哌酮钠舒巴坦钠安徽威尔曼制药有限公司CYHB2350857 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称类型受理号阿戈美拉汀片江苏和晨药业有限公司;昆山龙灯瑞迪制药有限公司4CYHS2404488阿立哌唑口崩片哈尔滨三联药业股份有限公司3CYHS2404560阿立哌唑口崩片哈尔滨三联药业股份有限公司3CYHS2404559阿莫西林克拉维酸钾干混悬剂山东益康药业股份有限公司4CYHS2404590阿瑞匹坦注射液山东齐都药业有限公司3CYHS2404598艾曲泊帕乙醇胺干混悬剂广州市联瑞制药有限公司3CYHS2404528艾托格列净片山东朗诺制药有限公司4CYHS2404557氨茶碱注射液湖南赛隆药业（长沙）有限公司3CYHS2404595氨茶碱注射液湖南赛隆药业（长沙）有限公司3CYHS2404594氨磺必利口服溶液浙江浙北药业有限公司3CYHS2404541氨溴特罗口服溶液湖南九典制药股份有限公司3CYHS2404519氨溴特罗口服溶液南昌立健药业有限公司3CYHS2404538氨溴特罗口服溶液山东简道制药有限公司3CYHS2404517倍他米松磷酸钠注射液成都天台山制药股份有限公司3CYHS2404555苯磺酸美洛加巴林片成都苑东生物制药股份有限公司4CYHS2404569苯磺酸美洛加巴林片成都苑东生物制药股份有限公司4CYHS2404570苯磺酸美洛加巴林片成都苑东生物制药股份有限公司4CYHS2404571苯磺酸左氨氯地平片济南高华制药有限公司4CYHS2404475苯磺酸左氨氯地平片济南高华制药有限公司4CYHS2404474苯溴马隆片北京福元医药股份有限公司3CYHS2404558吡仑帕奈口服混悬液南京海纳制药有限公司4CYHS2404484波生坦分散片江苏天士力帝益药业有限公司4CYHS2404493布美他尼注射液中山万汉制药有限公司3CYHS2404577布美他尼注射液中山万汉制药有限公司3CYHS2404578布美他尼注射液河南群益医药科技开发有限公司;信合援生制药股份有限公司3CYHS2404492布瑞哌唑口崩片河北龙海药业有限公司3CYHS2404510布瑞哌唑口崩片河北龙海药业有限公司3CYHS2404509达格列净二甲双胍缓释片（Ⅰ）江苏万高药业股份有限公司4CYHS2404592达格列净二甲双胍缓释片（Ⅰ）新乡市常乐制药有限责任公司4CYHS2404561达格列净二甲双胍缓释片（Ⅱ）新乡市常乐制药有限责任公司4CYHS2404562达格列净二甲双胍缓释片（Ⅲ）新乡市常乐制药有限责任公司4CYHS2404563达格列净二甲双胍缓释片（Ⅲ）江苏万高药业股份有限公司4CYHS2404591达格列净片上海衡山药业有限公司4CYHS2404506蛋白琥珀酸铁口服溶液山东则正医药技术有限公司;华益泰康药业股份有限公司4CYHS2404465地夸磷索钠滴眼液江苏福邦药业有限公司4CYHS2404467地夸磷索钠滴眼液福建华耀医药科技有限公司;杭州民生药业股份有限公司4CYHS2404489地氯雷他定口服溶液浙江华润三九众益制药有限公司;天大药业（珠海）有限公司3CYHS2404549地屈孕酮片北京金城泰尔制药有限公司;浙江赛默制药有限公司4CYHS2404601低钙腹膜透析液(乳酸盐-G1.5%)广东科泓药业有限公司4CYHS2404583对乙酰氨基酚片重庆药友制药有限责任公司3CYHS2404564对乙酰氨基酚维生素C泡腾片江苏和晨药业有限公司3CYHS2404600多巴丝肼片河北龙海药业有限公司4CYHS2404523二羟丙茶碱注射液江西科为制药有限公司;亚邦医药股份有限公司3CYHS2404553二十碳五烯酸乙酯软胶囊博瑞制药（苏州）有限公司4CYHS2404522非那雄胺片江苏知原药业股份有限公司4CYHS2404532非那雄胺片江苏知原药业股份有限公司4CYHS2404531非奈利酮片湖南慧泽生物医药科技有限公司;湖南九典制药股份有限公司4CYHS2404544氟比洛芬凝胶贴膏江苏万高药业股份有限公司4CYHS2404573复方电解质注射液(Ⅴ)湖南科伦制药有限公司3CYHS2404500复方磺胺甲噁唑注射液苏州伏生医药科技有限公司;寿光富康制药有限公司3CYHS2404534富马酸伏诺拉生片中曦（福建）药业有限公司;江苏万高药业股份有限公司4CYHS2404582富马酸伏诺拉生片中曦（福建）药业有限公司;江苏万高药业股份有限公司4CYHS2404581富马酸伏诺拉生片浙江九洲生物医药有限公司;浙江四维医药科技有限公司4CYHS2404477富马酸伏诺拉生片浙江九洲生物医药有限公司;浙江四维医药科技有限公司4CYHS2404476富马酸酮替芬滴眼液浙江恒研医药科技有限公司;浙江赛默制药有限公司3CYHS2404546富马酸依美斯汀滴眼液南京海纳制药有限公司4CYHS2404471枸橼酸托瑞米芬片上海安必生制药技术有限公司;吉林四环制药有限公司4CYHS2404547甲磺酸沙芬酰胺片齐鲁制药有限公司4CYHS2404586甲磺酸沙芬酰胺片杭州和康药业有限公司4CYHS2404580甲磺酸沙芬酰胺片杭州和康药业有限公司4CYHS2404579甲磺酸沙芬酰胺片齐鲁制药有限公司4CYHS2404587甲磺酸沙芬酰胺片华润赛科药业有限责任公司4CYHS2404527甲氧氯普胺片石家庄四药有限公司3CYHS2404607甲氧氯普胺片浙江百代医药科技有限公司;浙江赛默制药有限公司3CYHS2404551甲氧氯普胺片浙江百代医药科技有限公司;浙江赛默制药有限公司3CYHS2404552精氨酸布洛芬颗粒赫力昂（苏州）制药有限公司4CYHS2404482聚乙二醇4000散(儿童型)重庆赛诺生物药业股份有限公司3CYHS2404521卡铂注射液云南植物药业有限公司4CYHS2404545卡格列净片江西同和药业股份有限公司;江苏联环药业股份有限公司4CYHS2404536卡格列净片江西同和药业股份有限公司;江苏联环药业股份有限公司4CYHS2404535拉西地平片湖南普道医药技术有限公司;湖南九典制药股份有限公司4CYHS2404593利丙双卡因乳膏常州康普药业有限公司4CYHS2404485利丙双卡因乳膏常州康普药业有限公司4CYHS2404483利丙双卡因乳膏常州康普药业有限公司4CYHS2404481利福霉素钠注射液广东星昊药业有限公司3CYHS2404498利福霉素钠注射液广东星昊药业有限公司3CYHS2404499硫代硫酸钠注射液成都药宜立康医药科技有限公司;中玉制药（海口）有限公司3CYHS2404589硫代硫酸钠注射液长春澜江医药科技有限公司;成都硕德药业有限公司3CYHS2404508硫酸阿托品注射液烟台万润药业有限公司;烟台鲁银药业有限公司3CYHS2404615铝碳酸镁混悬液湖南普道医药技术有限公司;湖南九典制药股份有限公司3CYHS2404466氯化琥珀胆碱注射液成都欣捷高新技术开发股份有限公司;四川美大康佳乐药业有限公司3CYHS2404503氯化琥珀胆碱注射液成都欣捷高新技术开发股份有限公司;四川美大康佳乐药业有限公司3CYHS2404502氯化钾注射液河南普瑞药业有限公司3CYHS2404516氯化钾注射液河南普瑞药业有限公司3CYHS2404518氯硝西泮注射液国药集团工业有限公司廊坊分公司3CYHS2404609罗沙司他胶囊天方药业有限公司4CYHS2404504罗沙司他胶囊天方药业有限公司4CYHS2404505罗沙司他胶囊浙江百代医药科技有限公司;浙江赛默制药有限公司4CYHS2404480罗沙司他胶囊浙江百代医药科技有限公司;浙江赛默制药有限公司4CYHS2404479洛索洛芬钠口服溶液北京民康百草医药科技有限公司;山西同达药业有限公司3CYHS2404511马来酸曲美布汀片浙江昂利康制药股份有限公司;浙江赛默制药有限公司3CYHS2404602马来酸曲美布汀片浙江昂利康制药股份有限公司;浙江赛默制药有限公司3CYHS2404603吗啉硝唑氯化钠注射液广州大光制药有限公司;山东华鲁制药有限公司4CYHS2404608美沙拉秦肠溶片牡丹江恒远药业股份有限公司;浙江赛默制药有限公司4CYHS2404574美沙拉秦灌肠液杭州和泽坤元药业有限公司;浙江鼎泰药业股份有限公司4CYHS2404554米诺地尔搽剂广东恒健制药有限公司3CYHS2404576米诺地尔搽剂沈阳三生制药有限责任公司;浙江三生蔓迪药业有限公司3CYHS2404469米诺地尔搽剂沈阳三生制药有限责任公司;浙江三生蔓迪药业有限公司3CYHS2404470钠钾镁钙注射液中国大冢制药有限公司3CYHS2404568尼莫地平注射液南京卡文迪许生物工程技术有限公司;远大医药（中国）有限公司4CYHS2404613培哚普利氨氯地平片(Ⅲ)安徽佳和药业有限公司4CYHS2404520匹维溴铵片广东稳健药业有限公司;华益药业科技（安徽）有限公司4CYHS2404584普瑞巴林口服溶液岳阳新华达制药有限公司3CYHS2404462屈螺酮炔雌醇片(Ⅱ)昆明南疆制药有限公司;武汉九珑人福药业有限责任公司4CYHS2404537乳果糖口服溶液山东泽宇生物有限公司;莱阳市江波制药有限责任公司4CYHS2404565乳果糖口服溶液山东泽宇生物有限公司;莱阳市江波制药有限责任公司4CYHS2404566乳果糖口服溶液翎耀生物科技（上海）有限公司;安徽新世纪药业有限公司4CYHS2404543乳果糖口服溶液翎耀生物科技（上海）有限公司;安徽新世纪药业有限公司4CYHS2404542乳果糖口服溶液江苏联环药业股份有限公司4CYHS2404495乳果糖口服溶液江苏联环药业股份有限公司4CYHS2404494噻托溴铵/奥达特罗吸入喷雾剂艾特美（苏州）医药科技有限公司;博瑞制药（苏州）有限公司4CYHS2404540沙库巴曲缬沙坦钠片国药集团致君（深圳）坪山制药有限公司4CYHS2404464双氯芬酸二乙胺乳胶剂苏州高迈药业有限公司;药源生物科技（启东）有限公司4CYHS2404507他克莫司软膏海南海神同洲制药有限公司4CYHS2404524他克莫司软膏海南海神同洲制药有限公司4CYHS2404525头孢克洛缓释片(Ⅱ)广州白云山医药集团股份有限公司白云山制药总厂;金鸿药业股份有限公司4CYHS2404597托吡酯口服溶液杭州和康药业有限公司;华益药业科技（安徽）有限公司3CYHS2404585维生素B12滴眼液石家庄格瑞药业有限公司4CYHS2404490维生素B12滴眼液石家庄格瑞药业有限公司4CYHS2404491维生素B6注射液广东君康药业有限公司;珠海润都制药股份有限公司3CYHS2404604维生素B6注射液江苏九旭药业有限公司3CYHS2404599维生素B6注射液湖北广济药业股份有限公司;朗天药业（湖北）有限公司3CYHS2404486维生素K1注射液烟台鲁银药业有限公司3CYHS2404497维生素K1注射液烟台鲁银药业有限公司3CYHS2404496维生素K滴剂江苏万高药业股份有限公司3CYHS2404515乌帕替尼缓释片江苏飞马药业有限公司4CYHS2404539西咪替丁注射液江西科为制药有限公司;亚邦医药股份有限公司3CYHS2404605西咪替丁注射液石家庄四药有限公司3CYHS2404606西咪替丁注射液泽田（山东）药业有限公司;山东齐都药业有限公司3CYHS2404501硝酸甘油舌下片汇科德晟（广东）医学技术有限公司;四川宏明博思药业有限公司4CYHS2404468盐酸倍他司汀片上海理想制药有限公司3CYHS2404514盐酸苯海拉明注射液苏州朗科生物技术股份有限公司;南京臣功制药股份有限公司3CYHS2404513盐酸苯海拉明注射液苏州朗科生物技术股份有限公司;南京臣功制药股份有限公司3CYHS2404512盐酸多沙普仑注射液湖北简诚博泰医药有限公司;湖北津药药业股份有限公司3CYHS2404611盐酸多沙普仑注射液江苏九旭药业有限公司3CYHS2404612盐酸非索非那定口服混悬液南京海纳制药有限公司3CYHS2404550盐酸莫西沙星氯化钠注射液四川太平洋药业有限责任公司4CYHS2404567盐酸莫西沙星片郑州韩都药业集团有限公司4CYHS2404526盐酸普罗帕酮注射液河北桥洲医药科技有限公司;新乡市常乐制药有限责任公司3CYHS2404572盐酸缬更昔洛韦片Bluepharma Genéricos - Comércio de Medicamentos, S.A.5.2JYHS2400066盐酸溴己新片白云山东泰商丘药业有限公司3CYHS2404529盐酸左西替利嗪口服溶液亚宝药业四川制药有限公司3CYHS2404473盐酸左西替利嗪口服溶液亚宝药业四川制药有限公司3CYHS2404472伊布替尼胶囊北京双鹭药业股份有限公司4CYHS2404588伊布替尼片湖南科伦制药有限公司3CYHS2404530依达拉奉右莰醇注射用浓溶液南京优科制药有限公司4CYHS2404548依折麦布片江西施美药业股份有限公司4CYHS2404533乙酰半胱氨酸口服溶液舒美奇成都生物科技有限公司;成都硕德药业有限公司3CYHS2404478重酒石酸间羟胺注射液河南群益医药科技开发有限公司;信合援生制药股份有限公司3CYHS2404463重酒石酸去甲肾上腺素注射液山西振东泰盛制药有限公司3CYHS2404614注射用硫酸艾沙康唑华润双鹤药业股份有限公司4CYHS2404575注射用特利加压素天津红日药业股份有限公司;哈尔滨三联药业股份有限公司4CYHS2404610注射用盐酸罗沙替丁醋酸酯山东新华鲁抗医药有限公司;山东裕欣药业有限公司3CYHS2404487注射用唑来膦酸浓溶液云南药科院生物医药股份有限公司;楚雄和创药业有限责任公司4CYHS2404596左炔诺孕酮片乐福思健康产业股份公司4CYHS2404556 4、新增一致性评价补充申报药品名称企业名称受理号阿仑膦酸钠片海南全星制药有限公司CYHB2450638阿昔莫司胶囊地奥集团成都药业股份有限公司CYHB2450626碘海醇注射液福安药业集团宁波天衡制药有限公司CYHB2450640对乙酰氨基酚片吉林省尚城药业有限公司;吉林省罗邦药业有限公司CYHB2450643己酮可可碱注射液江苏康缘药业股份有限公司CYHB2450622硫酸阿托品注射液信合援生制药股份有限公司CYHB2450636诺氟沙星片万邦德制药集团有限公司CYHB2450642碳酸氢钠注射液湖南康源制药有限公司CYHB2450639维生素B6注射液山东方明药业集团股份有限公司CYHB2450623西咪替丁片万邦德制药集团有限公司CYHB2450628盐酸氨溴索片国药集团汕头金石制药有限公司CYHB2450627盐酸伐昔洛韦片丽珠集团丽珠制药厂CYHB2450641盐酸林可霉素注射液国药集团容生制药有限公司CYHB2450624盐酸林可霉素注射液华中药业股份有限公司CYHB2450625盐酸溴己新片山西立业制药有限公司CYHB2450635注射用阿莫西林钠克拉维酸钾中山市力恩普制药有限公司;国药集团威奇达药业有限公司CYHB2450634注射用阿莫西林钠克拉维酸钾中山市力恩普制药有限公司;国药集团威奇达药业有限公司CYHB2450632注射用阿莫西林钠克拉维酸钾中山市力恩普制药有限公司;国药集团威奇达药业有限公司CYHB2450633注射用氨苄西林钠海南海灵化学制药有限公司CYHB2450629注射用氨苄西林钠海南海灵化学制药有限公司CYHB2450631注射用氨苄西林钠海南海灵化学制药有限公司CYHB2450630注射用甲磺酸加贝酯常州四药制药有限公司CYHB2450621注射用胸腺法新天津红日药业股份有限公司;哈尔滨三联药业股份有限公司CYHB2450637 数据来源：摩熵医药 用摩熵药筛小程序，随时随地查周报